Neuroendocrine Tumor Treatment Market, Size, Share, Opportunities and Forecast, 2020-2027

SKU: DPH122 | Last Updated On: Jun 10 2020 | No. of Pages: 203 | Available Formats

> Global Neuroendocrine Tumor Treatment Market Expected to reach a high CAGR of 10.4% By 2027: DataM Intelligence

Global Neuroendocrine Tumor Treatment Market is segmented By Therapy type (Somatostatin analogs (SSAs), Targeted therapy, Others), By Indication (Small intestine, Lungs, Pancreas, Gastrointestinal, Others), By Route of administration (Oral, Parenteral), By End-user (Hospitals, Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2020-2027

 

Market Overview

The Global Neuroendocrine Tumor Treatment Market is expected to grow at a CAGR of 10.4% during the forecasting period (2020-2027).

The neuroendocrine tumor is a rare tumor that arises from the specialized body cells, called neuroendocrine cells. It may occur anywhere in the body but mostly occurs in the pancreas, digestive tract, lungs, rectum, and appendix. The neuroendocrine tumor can be either benign or malignant.

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The major driving forces are the increasing prevalence of neuroendocrine carcinoma, technological advancements, rising awareness among people, and the growing number of government initiatives.

The prevalence of Neuroendocrine tumors is increasing across the globe, though being a rare disease as it is reported that more than 12,000 people are found to be affected by neuroendocrine tumors every year in the US. Therefore the increasing prevalence of neuroendocrine tumors helps in the adoption rate of the drugs for the treatment of this rare disease.

The presence of ongoing research and development activities is expected to drive the market growth. For instance, few ongoing clinical trials include RAD 001 to treat advanced midgut NETs, Lanreotide Autogel for non-functional tumors, and NET-01 chemotherapy for the pancreatic tumors. Also, ongoing R&D activities in detection techniques, like Ga labeled radionucleotide therapies and the radiofrequency ablation technique, are the key factors driving the demand market.

Below is one among the huge promising pipeline for neuroendocrine tumor treatment, which is expected to boost market growth.

Company

Drug

Indication

Phase

Anticipated launch

Dana-Farber Cancer Institute in collaboration with Eli Lilly and Company

Ramucirumab with Somatostatin Analog

Carcinoid Tumors

Phase 2

2023

The presence of increasing investments by government organizations is expected to drive the market growth. For instance, organizations, such as the Neuroendocrine Tumor Research Foundation (NETRF), has invested more than 1.5 USD million in the development of advanced radiation therapy called Peptide Receptor Radionuclide Therapy (PRRT).

Rising awareness is expected to accelerate market growth over the forecast period. For instance, several organizations across the world are conducting national and international programs to increase awareness about the neuroendocrine tumors for early diagnosis of the disease. For instance, the International Neuroendocrine Cancer Alliance observes the neuroendocrine day on November 10, every year. Such awareness programs also help vendors to understand opportunities in the current market scenario and invest in research to develop new therapies.

However, the high cost of development and the onset of side effects are expected to hinder the market growth.

The onset of side effects is likely to hamper the growth of the market over the forecast period. The possible side effects include high blood sugars, the development of gallstones, and mild digestive system upset, such as bloating and nausea.

Market Segmentation Analysis

By therapy type, the neuroendocrine tumor treatment market can be segmented into somatostatin analogs (SSAs), targeted therapy, and others.

The Somatostatin product segment is expected to propel the market growth over the forecast period, owing to the safe treatment procedure offered by SSA. SSAs are usually used to treat patients who are resistant to surgery and radiation therapy. Many somatostatin analogs are currently under clinical trials and waiting for approval. For instance,

Company/Organization

Drug

Study Title

Phase

Anticipated launch

Tarveda Therapeutics

PEN-221

PEN-221 in somatostatin receptor 2 expressing advanced cancers including neuroendocrine and small cell lung cancers

Phase 1/2a

2020

University Health Network, Toronto

Lutetium-177 Octreotate

Patients with 68Ga-DOTATATE somatostatin receptor-positive neuroendocrine tumor

-

2024

Universitaire Ziekenhuizen Leuven

Al18F-NOTA-octreotide

Al18F-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors

Phase 1

December 2019

The targeted therapy segment is expected to grow at a significant rate over the forecast period, owing to the presence of FDA approved drugs. For instance, in February 2016, Everolimus (Afinitor), a targeted therapy approved by the US FDA for the treatment of advanced NETs of the lung, GI tract, and pancreas. This drug can help to slow down the growth of these tumors in some patients, but it does not usually shrink tumors. Another targeted therapy, sunitinib (Sutent), which targets a protein called VEGF, is also approved by the US FDA for the treatment of pancreatic NETs. Thus, the presence of FDA approved drugs for neuroendocrine tumor treatment is driving the market.

Source: DataM Intelligence Analysis (2019)

By indication, the neuroendocrine tumor treatment market can be segmented into the small intestine, lungs, pancreas, gastrointestinal, and others.

The small intestine segment is expected to grow at a high rate over the forecast period, as the GI tract is more prone to develop NETs. As per the statistics published in the investor presentation of Novartis AG, GI comprised 61% of the total NETs, and among them, tumors in the small intestine were the most common ones.

The pancreas segment is expected to grow at a high rate over the forecast period, owing to the increasing R&D investments for the development of novel therapies for pancreatic NETs. For instance,

Company/Organization

Indication

Anticipated launch

Hutchison Medipharma Limited

For the treatment of advanced pancreatic neuroendocrine tumor

2020

University Hospital, Strasbourg, France

Clinicopathological assessment of pancreatic neuroendocrine tumors and carcinomas in the Alsace region

2020

 

By route of administration, the neuroendocrine tumor treatment market can be segmented into oral and parenteral.

The oral segment is expected to grow at a high rate over the forecast period, owing to the presence of FDA approved oral drugs. For instance, in February 2017, the FDA approved Xermelo (telotristat ethyl), in combination with a somatostatin analog. It is an oral drug that reduces the overproduction of seratonin that some NETs cause and, in so doing, relieves diarrhea.

Geographical Analysis

Geographically, the global neuroendocrine tumor treatment market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is dominating the global neuroendocrine tumor treatment market in 2018 and is estimated to hold significant market size over the forecast period (2020-2027) owing to supportive insurance policies in the region facilitating NET treatment, like Medicare, Medicaid, and Tricare. Also, sophisticated healthcare facilities and high R&D expenditure by pharmaceutical companies and regional government for cancer research are other factors driving the market.

The increasing prevalence of neuroendocrine cancer is expected to drive market growth over the forecast period. For instance, according to the statistics published by the American Society of Clinical Oncology (ASCO), in 2016, around 8,000 adults in the US were diagnosed with GI tract-carcinoid tumors. Also, as per Cancer.Net, it is estimated that more than 12,000 people in the US are diagnosed with a NET every year, and approximately 170,000 people are living with 1. This increasing prevalence of neuroendocrine tumors in the GI tract is expected to drive the market.

Also, the presence of ongoing research activities by several organizations is expected to drive the market growth over the forecast period.

Company/Organization

Drug/Test

Indication

Phase

Anticipated launch

University Health Network, Toronto

68Ga -DOTATATE PET scans

68Ga-DOTATATE PET for Management of Neuroendocrine Tumors

-

2024

National Cancer Institute (NCI)

National Institutes of Health (NIH)

Gallium 68 Pentixafor

neuroendocrine tumors

Early Phase 1

2020

Source: DataM Intelligence Analysis (2019)

Competitive Landscape

The major players operating in the global neuroendocrine tumor treatment market are Amgen, Inc, Bristol-Myers Squibb, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Ipsen Pharmaceuticals, Novartis AG, Hutchinson Medipharma Limited, Tarveda Therapeutics, Progenics Pharmaceuticals, and Pfizer Inc.

The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the neuroendocrine tumor treatment market globally. For instance,

On July 30, 2018, Progenics Pharmaceuticals, Inc. announced that the US FDA had approved the New Drug Application for AZEDRA (iobenguane I 131) injection for the treatment of pheochromocytoma or paraganglioma who require systemic anticancer therapy.  

On July 12, 2018, Novartis launched its Galaxies of Hope app, a unique digital experience created to support the neuroendocrine tumor (NET) community.

In January 2018, Novartis AG received FDA approval for Luthatera, radiolabelled somatostatin analog for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

In October 2017, Novartis announced the acquisition of Advanced Accelerator Applications, a radiopharmaceutical company, to expand its oncology product portfolio.

In February 2016, Novartis received FDA approval for Afinitor for the treatment of both GI and lung neuroendocrine tumors.

Why Purchase the Report?

  • Visualize the composition of the global neuroendocrine tumor treatment market across each therapy type, indication, route of administration, and end-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in the global neuroendocrine tumor treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the global neuroendocrine tumor treatment market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Type mapping in excel for the key Services of all major market players.

The Global Neuroendocrine Tumor Treatment Market report would provide access to an approx, 72 market data tables, 63 figures, and 220 pages.

Target Audience:

  • Equipment Suppliers/ Buyers
  • Type Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

 

Related Reports:

Neuroendocrine Cancer Market

Gastrointestinal Stromal Tumor (GIST) – Pipeline Insights

 

 

Table of Contents

  1. Neuroendocrine Tumor Treatment Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Neuroendocrine Tumor Treatment Market – Market Definition and Overview

  3. Neuroendocrine Tumor Treatment  Market – Executive Summary

    1. Market Snippet by Therapy type
    2. Market Snippet by Indication
    3. Market Snippet by Route of administration
    4. Market Snippet by End-user
  4. Neuroendocrine Tumor Treatment Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. The increasing prevalence of neuroendocrine tumors
        2. The presence of ongoing research and development activities
      2. Restraints
        1. The onset of side effects
      3. Opportunity
      4. Impact Analysis
  5. Neuroendocrine Tumor Treatment Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Regulatory Analysis
    3. Supply Chain Analysis
    4. Pricing Analysis
    5. Unmet Needs
  6. Neuroendocrine Tumor Treatment Market - By Therapy type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy type
      2. Market Attractiveness Index, By Therapy type Segment
    2. Somatostatin analogs (SSAs)*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Targeted therapy
    4. Others
  7. Neuroendocrine Tumor Treatment Market - By Indication

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
      2. Market Attractiveness Index, By Indication Segment
    2. Small intestine*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth
    3. Lungs
    4. Pancreas
    5. Gastrointestinal
    6. Others
  8. Neuroendocrine Tumor Treatment Market - By Route of administration

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
      2. Market Attractiveness Index, By Route of administration Segment
    2. Oral*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Parenteral
  9. Neuroendocrine Tumor Treatment Market - By End-user

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      2. Market Attractiveness Index, By End-user Segment
    2. Hospitals *
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Clinics
    4. Others
  10. Neuroendocrine Tumor Treatment Market - By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. The U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. The U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. The Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
  11. Neuroendocrine Tumor Treatment Market Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis
  12. Neuroendocrine Tumor Treatment Market Company Profiles

    1. Amgen, Inc*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Bristol-Myers Squibb
    3. Eli Lilly & Company
    4. F. Hoffmann-La Roche Ltd.
    5. Ipsen pharmaceuticals
    6. Novartis AG
    7. Pfizer Inc
    8. Hutchinson Medipharma Limited
    9. Tarveda Therapeutics
    10. Progenics Pharmaceuticals (**List not exhaustive)
  13. Neuroendocrine Tumor Treatment Market – Premium Insights

  14. Neuroendocrine Tumor Treatment Market – Data-M

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables & Figures

 List of Tables

TABLE 01 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2018, 2022 & 2027 ($ MILLION)

TABLE 02 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2018, 2022 & 2027 ($ MILLION)

TABLE 03 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2018, 2022 & 2027 ($ MILLION)

TABLE 04 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2018, 2022 & 2027 ($ MILLION)

TABLE 05 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2018, 2022 & 2027 ($ MILLION)

TABLE 06 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2018, 2022 & 2027 ($ MILLION)

TABLE 07 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2017-2027 ($ MILLION)

TABLE 08 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2018, 2022 & 2027 ($ MILLION)

TABLE 09 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2017-2027 ($ MILLION)

TABLE 10 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2017-2027 ($ MILLION)

TABLE 11 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2017-2027 ($ MILLION)

TABLE 12 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2018, 2022 & 2027 ($ MILLION)

TABLE 13 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 14 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2018, 2022 & 2027 ($ MILLION)

TABLE 15 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 16 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2018, 2022 & 2027 ($ MILLION)

TABLE 17 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 18 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2017-2027 ($ MILLION)

TABLE 19 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2017-2027 ($ MILLION)

TABLE 20 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 21 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 22 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 23 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2017-2027 ($ MILLION)

TABLE 24 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2017-2027 ($ MILLION)

TABLE 25 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 26 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 27 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 28 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2017-2027 ($ MILLION)

TABLE 29 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2017-2027 ($ MILLION)

TABLE 30 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 31 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 32 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 33 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2017-2027 ($ MILLION)

TABLE 34 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2017-2027 ($ MILLION)

TABLE 35 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 36 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 37 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 38 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY THERAPY TYPE, 2017-2027 ($ MILLION)

TABLE 39 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY INDICATION, 2017-2027 ($ MILLION)

TABLE 40 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 41 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 42 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 43 AMGEN, INC: OVERVIEW

TABLE 44 AMGEN, INC: PRODUCT PORTFOLIO

TABLE 45 AMGEN, INC: KEY DEVELOPMENTS

TABLE 46 BRISTOL-MYERS SQUIBB: OVERVIEW

TABLE 47 BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO

TABLE 48 BRISTOL-MYERS SQUIBB: KEY DEVELOPMENTS

TABLE 49 ELI LILLY & COMPANY: OVERVIEW

TABLE 50 ELI LILLY & COMPANY: PRODUCT PORTFOLIO

TABLE 51 ELI LILLY & COMPANY: KEY DEVELOPMENTS

TABLE 52 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW

TABLE 53 F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 54 F. HOFFMANN-LA ROCHE LTD.: KEY DEVELOPMENTS

TABLE 55 IPSEN PHARMACEUTICALS: OVERVIEW

TABLE 56 IPSEN PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 57 IPSEN PHARMACEUTICALS: KEY DEVELOPMENTS

TABLE 58 NOVARTIS AG: OVERVIEW

TABLE 59 NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 60 NOVARTIS AG: KEY DEVELOPMENTS

TABLE 61 PFIZER INC: OVERVIEW

TABLE 62 PFIZER INC: PRODUCT PORTFOLIO

TABLE 63 PFIZER INC: KEY DEVELOPMENTS

TABLE 64 HUTCHINSON MEDIPHARMA LIMITED: OVERVIEW

TABLE 65 HUTCHINSON MEDIPHARMA LIMITED: PRODUCT PORTFOLIO

TABLE 66 HUTCHINSON MEDIPHARMA LIMITED: KEY DEVELOPMENTS

TABLE 67 TARVEDA THERAPEUTICS: OVERVIEW

TABLE 68 TARVEDA THERAPEUTICS: PRODUCT PORTFOLIO

TABLE 69 TARVEDA THERAPEUTICS: KEY DEVELOPMENTS

TABLE 70 PROGENICS PHARMACEUTICALS: OVERVIEW

TABLE 71 PROGENICS PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 72 PROGENICS PHARMACEUTICALS: KEY DEVELOPMENTS

 

LIST OF FIGURES 

FIGURE 01 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY THERAPY TYPE, 2018 & 2027 (%) 

FIGURE 02 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY INDICATION, 2018 & 2027 (%)

FIGURE 03 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2018 & 2027 (%)

FIGURE 04 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%) 

FIGURE 05 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%) 

FIGURE 06 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%) 

FIGURE 07 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 08 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET Y-O-Y GROWTH, BY THERAPY TYPE, 2018-2027 (%) 

FIGURE 09 SOMATOSTATIN ANALOGS (SSAS): GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 10 TARGETED THERAPY: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 11 OTHERS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 12 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET Y-O-Y GROWTH, BY INDICATION, 2018-2027 (%) 

FIGURE 13 SMALL INTESTINE: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 14 LUNGS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 15 PANCREAS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 16 GASTROINTESTINAL: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 17 OTHERS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 18 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET Y-O-Y GROWTH, BY END-USER, 2018-2027 (%) 

FIGURE 19 HOSPITALS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 20 CLINICS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 21 OTHERS: GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 22 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET Y-O-Y GROWTH, BY REGION, 2018-2027 (%) 

FIGURE 23 GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET Y-O-Y GROWTH, BY COUNTRY, 2018-2027 (%) 

FIGURE 24 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 25 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY THERAPY TYPE, 2018 & 2027 (%) 

FIGURE 26 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY INDICATION, 2018 & 2027 (%) 

FIGURE 27 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%) 

FIGURE 28 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%) 

FIGURE 29 NORTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%) 

FIGURE 30 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 31 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY THERAPY TYPE, 2018 & 2027 (%) 

FIGURE 32 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY INDICATION, 2018 & 2027 (%) 

FIGURE 33 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%) 

FIGURE 34 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%) 

FIGURE 35 SOUTH AMERICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%) 

FIGURE 36 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 37 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY THERAPY TYPE, 2018 & 2027 (%) 

FIGURE 38 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY INDICATION, 2018 & 2027 (%) 

FIGURE 39 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%) 

FIGURE 40 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%) 

FIGURE 41 EUROPE NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%) 

FIGURE 42 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 43 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY THERAPY TYPE, 2018 & 2027 (%) 

FIGURE 44 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY INDICATION, 2018 & 2027 (%) 

FIGURE 45 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%) 

FIGURE 46 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%) 

FIGURE 47 ASIA-PACIFIC NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%) 

FIGURE 48 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 49 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY THERAPY TYPE, 2018 & 2027 (%) 

FIGURE 50 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY INDICATION, 2018 & 2027 (%) 

FIGURE 51 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%) 

FIGURE 52 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%) 

FIGURE 53 MIDDLE EAST & AFRICA NEUROENDOCRINE TUMOR TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%) 

FIGURE 54 AMGEN, INC: FINANCIALS 

FIGURE 55 BRISTOL-MYERS SQUIBB: FINANCIALS 

FIGURE 56 ELI LILLY & COMPANY: FINANCIALS 

FIGURE 57 F. HOFFMANN-LA ROCHE LTD.: FINANCIALS 

FIGURE 58 IPSEN PHARMACEUTICALS: FINANCIALS 

FIGURE 59 NOVARTIS AG: FINANCIALS 

FIGURE 60 PFIZER INC: FINANCIALS

FIGURE 61 HUTCHINSON MEDI PHARMA LIMITED: FINANCIALS

FIGURE 62 TARVEDA THERAPEUTICS: FINANCIALS

FIGURE 63 PROGENICS PHARMACEUTICALS: FINANCIALS

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!

linkedinpinterest